ZEJULA
Total Payments
$420.4M
Transactions
59,571
Doctors
10,149
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $67.4M | 2,083 | 1,072 |
| 2023 | $50.1M | 5,990 | 2,781 |
| 2022 | $40.3M | 7,323 | 2,984 |
| 2021 | $30.9M | 6,127 | 2,620 |
| 2020 | $16.8M | 3,742 | 1,707 |
| 2019 | $89.4M | 12,992 | 3,144 |
| 2018 | $59.0M | 11,971 | 3,222 |
| 2017 | $66.6M | 9,343 | 2,229 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $406.4M | 11,107 | 96.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8.6M | 2,885 | 2.1% |
| Consulting Fee | $2.0M | 906 | 0.5% |
| Travel and Lodging | $1.7M | 4,166 | 0.4% |
| Food and Beverage | $1.3M | 39,708 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $242,425 | 136 | 0.1% |
| Education | $109,239 | 661 | 0.0% |
| Grant | $8,500 | 2 | 0.0% |
Payments by Type
Research
$406.4M
11,107 transactions
General
$14.0M
48,464 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | TESARO, Inc. | $52.2M | 22 |
| PHASE 12 CLINICAL STUDY OF NIRAPARIB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND IN PATIENTS WITH RECURRENT OVARIAN CANCER | TESARO, Inc. | $23.5M | 0 |
| A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | TESARO, Inc. | $21.8M | 9 |
| PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY | TESARO, Inc. | $18.9M | 0 |
| 0000000000000000000000000000000000000000000000000000000000000000223708 | GlaxoSmithKline, LLC. | $15.4M | 0 |
| 0000000000000000000000000000000000000000000000000000000000000000222233 | GlaxoSmithKline, LLC. | $14.7M | 0 |
| A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER | TESARO, Inc. | $12.7M | 0 |
| A PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER FIRST | TESARO, Inc. | $11.8M | 0 |
| PHASE 2, MULTI-ARM STUDY OF NIRAPARIB ADMINISTERED ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER | TESARO, Inc. | $11.0M | 0 |
| 214357 | GlaxoSmithKline, LLC. | $7.8M | 0 |
| CROSSOVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF NIRAPARIB TABLET COMPARED TO NIRAPARIB CAPSULE | TESARO, Inc. | $7.5M | 0 |
| 0000000000000000000000000000000000000000000000000000000000000000214387 | GlaxoSmithKline, LLC. | $7.3M | 0 |
| Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | TESARO, Inc. | $6.6M | 0 |
| 0000000000000000000000000000000000000000000000000000000000000000214357 | GlaxoSmithKline, LLC. | $6.4M | 0 |
| 214346 | GlaxoSmithKline, LLC. | $6.3M | 0 |
| 218046 | GlaxoSmithKline, LLC. | $6.2M | 0 |
| 214387 | GlaxoSmithKline, LLC. | $6.1M | 0 |
| 0000000000000000000000000000000000000000000000000000000000000000214346 | GlaxoSmithKline, LLC. | $5.9M | 0 |
| PHASE 2 MULTICOHORT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL TREATMENT COMBINATIONS IN PATIENTS WITH RECURRENT OVARIAN CANCER OPAL | TESARO, Inc. | $5.6M | 0 |
| 0000000000000000000000000000000000000000000000000000000000000000214385 | GlaxoSmithKline, LLC. | $5.5M | 0 |
Top Doctors Receiving Payments for ZEJULA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Sukhdeep Kaur | — | Philadelphia, PA | $406.2M | 10,730 |
| , MD | Gynecologic Oncology | Phoenix, AZ | $634,895 | 594 |
| , DO | Gynecologic Oncology | Albany, NY | $481,665 | 353 |
| , MD | Gynecologic Oncology | Abington, PA | $455,826 | 412 |
| , MD | Obstetrics & Gynecology | San Jose, CA | $446,883 | 374 |
| , MD | Gynecologic Oncology | Pittsburgh, PA | $438,345 | 384 |
| , MD | Gynecologic Oncology | Iowa City, IA | $357,615 | 276 |
| , M.D | Gynecologic Oncology | Phoenix, AZ | $352,293 | 338 |
| Chirag Shah | Gynecologic Oncology | Seattle, WA | $281,378 | 319 |
| , D.O | Obstetrics & Gynecology | Kansas City, MO | $276,005 | 349 |
| , M.D | Gynecologic Oncology | Atlanta, GA | $268,773 | 298 |
| , MD | Obstetrics & Gynecology | Huntington, WV | $258,618 | 202 |
| , MD | Specialist | Seattle, WA | $239,977 | 225 |
| , MD | Gynecologic Oncology | Atlanta, GA | $237,147 | 200 |
| , M.D | Diagnostic Radiology | Boston, MA | $209,775 | 49 |
| , MD | Obstetrics & Gynecology | Fort Worth, TX | $209,269 | 186 |
| , MD | Obstetrics & Gynecology | Detroit, MI | $205,783 | 140 |
| , MD | Obstetrics & Gynecology | Hershey, PA | $197,839 | 155 |
| , M.D | Gynecologic Oncology | Tempe, AZ | $180,615 | 169 |
| , M.D | Obstetrics & Gynecology | Richmond, VA | $176,112 | 171 |
| , MD | Gynecologic Oncology | Portland, OR | $171,449 | 155 |
| , M.D | Specialist | Canton, OH | $158,818 | 163 |
| , M.D | Gynecologic Oncology | Orange, CA | $153,900 | 157 |
| , MD | Gynecologic Oncology | Orlando, FL | $145,986 | 126 |
| , MD | Obstetrics & Gynecology | Detroit, MI | $141,075 | 151 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $213.2M
- TESARO, Inc. $207.2M
Product Information
- Type Drug
- Total Payments $420.4M
- Total Doctors 10,149
- Transactions 59,571
About ZEJULA
ZEJULA is a drug associated with $420.4M in payments to 10,149 healthcare providers, recorded across 59,571 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2024. In 2024, $67.4M was paid across 2,083 transactions to 1,072 doctors.
The most common payment nature for ZEJULA is "Unspecified" ($406.4M, 96.7% of total).
ZEJULA is associated with 20 research studies, including "A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH HRD-POSITIVE ADVANCED OVARIAN CANCER FOLLOWING RESPONSE ON FRONT-LINE PLATINUM-BASED CHEMOTHERAPY" ($52.2M).